Literature DB >> 2642528

Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

H Mayumi1, R A Good.   

Abstract

A new method of cyclophosphamide (CP)-induced skin allograft tolerance in mice that can regularly overcome fully allogeneic (major H-2 plus non-H-2) antigen barriers in mice has been established. The components of the method are intravenous or intraperitoneal administration of 50-100 micrograms of anti-Thy-1.2 mAb on day -1, intravenous injection of 90 x 10(6) allogeneic spleen cells mixed with 30 x 10(6) allogeneic bone marrow cells from the same donor on day 0, and intraperitoneal injection of 200 mg/kg CP on day 2. In each of four fully allogeneic donor----recipient combinations, including C3H/HeJ (C3H; H-2k)----C57BL/6J(B6; H-2b), B6----C3H, BALB/cByJ (BALB; H-2d)----B6, and BALB----C3H, long-lasting survival of skin allografts was induced in most of the recipient mice. The specific tolerant state induced was dependent on the doses of the antibody and bone marrow cells used. The optimal timing of CP treatment to induce tolerance was found to be 1-3 d after the stimulating cell injection. Treatment with the anti-Thy-1.2 antibody together with CP on day 2 after the cell injection on day 0 also induced profound tolerance. In the B6 mice made tolerant of C3H with antibody, C3H spleen cells plus C3H bone marrow cells, and then CP, a minimal degree of stable mixed chimerism was established and the antitolerogen (C3H) immune responses examined here, including delayed footpad reaction (DFR), CTL activity, and capacity for antibody production against donor-strain antigens were abrogated in a tolerogen-specific manner. From cell transfer experiments, the mechanism of tolerance could be largely attributed to reduction of effector T cells reactive against the tolerogen, and strong suppressive influences that might prolong skin allograft survival directly were not detected in the tolerant mice. Moreover, pretreatment with anti-Thy-1.2 antibody or anti-L3T4 (CD4) antibody was more effective than pretreatment with anti-Lyt-1 (CD5) antibody or anti-Lyt-2 (CD8) antibody as an initial step in tolerance induction. These results suggest that permanent tolerance to fully allogeneic skin grafts may be induced because antibody given before the stimulating cell injection reduces the number of reactive T cells in the recipient mice. This antibody treatment may facilitate an antigen-stimulated destruction of responding and thus proliferating cells with CP by preventing a possibly less proliferative, more rapid maturation of reactive T cells or by destroying residual effector T cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642528      PMCID: PMC2189174          DOI: 10.1084/jem.169.1.213

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  59 in total

1.  PROLONGATION OF HOMOGRAFT SURVIVAL IN MICE WITH SINGLE DOSES OF CYCLOPHOSPHAMIDE.

Authors:  M C BERENBAUM; I N BROWN
Journal:  Nature       Date:  1963-10-05       Impact factor: 49.962

2.  Induction of tolerance by monoclonal antibody therapy.

Authors:  R J Benjamin; H Waldmann
Journal:  Nature       Date:  1986 Apr 3-9       Impact factor: 49.962

3.  L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens.

Authors:  B L Hamilton
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

4.  Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination.

Authors:  H Mayumi; K Himeno; N Tokuda; K Nomoto
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

5.  Drug-induced tolerance to allografts in mice. VI. Tolerance induction in H-2-haplotype-identical strain combinations in mice.

Authors:  H Mayumi; K Himeno; T Shin; K Nomoto
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

6.  Drug-induced tolerance to allografts in mice. V. Prolongation of skin graft survival in tolerant mice with combined immunosuppressive treatments.

Authors:  H Mayumi; K Kayashima; T Shin; K Nomoto
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

7.  Drug-induced tolerance to allografts in mice. X. Augmentation of split tolerance in murine combinations disparate at both H-2 and non-H-2 antigens by the use of spleen cells from donors preimmunized with recipient antigens.

Authors:  H Mayumi; K Himeno; N Tokuda; J L Fan; K Nomoto
Journal:  Immunobiology       Date:  1987-05       Impact factor: 3.144

8.  Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease.

Authors:  H Mayumi; K Himeno; K Tanaka; N Tokuda; J L Fan; K Nomoto
Journal:  Transplantation       Date:  1987-08       Impact factor: 4.939

9.  Drug-induced tolerance to allografts in mice II. Tolerance to tumor allografts of large doses associated with rejection of skin allografts and tumor allografts of small doses.

Authors:  H Mayumi; T Shin; K Himeno; K Nomoto
Journal:  Immunobiology       Date:  1985-03       Impact factor: 3.144

10.  Effector cells in allelic H-2 class I-incompatible skin graft rejection.

Authors:  T Ichikawa; E Nakayama; A Uenaka; M Monden; T Mori
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  40 in total

1.  Induction of Pancreatic Islet Graft Acceptance: The Role of Antigen Presenting Cells.

Authors:  Camillo Ricordi; Suzanne T Ildstad; Thomas E Starzl
Journal:  Transplant Sci       Date:  1992-04

2.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 3.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy.

Authors:  K Lee; V Nguyen; K-M Lee; S-M Kang; Q Tang
Journal:  Am J Transplant       Date:  2013-11-13       Impact factor: 8.086

5.  Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Authors:  Ashley T Munchel; Yvette L Kasamon; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2011-07-13       Impact factor: 3.020

6.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

7.  Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in rats.

Authors:  P M Markus; G Selvaggi; X Cai; J J Fung; T E Starzl
Journal:  Cell Transplant       Date:  1993 Jul-Aug       Impact factor: 4.064

Review 8.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

9.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

10.  Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming.

Authors:  T Maeda; M Eto; Y Nishimura; K Nomoto; Y Y Kong; K Nomoto
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.